{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:47:03Z","timestamp":1774028823366,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.retram.2025.103551","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T05:36:22Z","timestamp":1762580182000},"page":"103551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Italian expert consensus recommendations for the safe administration of high-dose methotrexate in children with cancer and for the use of glucarpidase to manage delayed methotrexate elimination and\/or high-dose methotrexate-induced acute kidney injury"],"prefix":"10.1016","volume":"73","author":[{"given":"Nicol\u00f2","family":"Peccatori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Ardissino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Cesaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Gaspari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Meazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Mura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4828-3893","authenticated-orcid":false,"given":"Carmelo","family":"Rizzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.retram.2025.103551_bib0001","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1182\/blood-2022-168710","article-title":"High-dose methotrexate-related toxicity in children with acute lymphoblastic leukemia","volume":"140","author":"Egnell Gustafsson","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.retram.2025.103551_bib0002","first-page":"4423","article-title":"Efficacy and association analysis of high-dose methotrexate in the treatment of children with acute lymphoblastic leukemia","volume":"17","author":"Gong","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.retram.2025.103551_bib0003","series-title":"StatPearls [Internet]","article-title":"Methotrexate","author":"Hanoodi","year":"2024"},{"issue":"12","key":"10.1016\/j.retram.2025.103551_bib0004","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.retram.2025.103551_bib0005","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/phar.2145","article-title":"Management of patients with acute methotrexate nephrotoxicity with high-dose leucovorin","volume":"38","author":"Flombaum","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.retram.2025.103551_bib0006","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.retram.2025.103551_bib0007","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute kidney injury in patients with cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.retram.2025.103551_bib0008","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/phar.1360","article-title":"Efficacy of glucarpidase (carboxypeptidase G2) in patients with acute kidney injury after high-dose methotrexate therapy","volume":"34","author":"Widemann","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.retram.2025.103551_bib0009","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/sj.bjc.6602337","article-title":"Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure","volume":"92","author":"Buchen","year":"2005","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.retram.2025.103551_bib0010","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1634\/theoncologist.12-11-1299","article-title":"Glucarpidase (carboxypeptidase G2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy","volume":"12","author":"Schwartz","year":"2007","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.retram.2025.103551_bib0011","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.20255","article-title":"High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma","volume":"100","author":"Widemann","year":"2004","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.retram.2025.103551_bib0012","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","article-title":"Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome","volume":"28","author":"Widemann","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.retram.2025.103551_bib0013","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.1997.15.5.2125","article-title":"Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction","volume":"15","author":"Widemann","year":"1997","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.retram.2025.103551_bib0014","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00432-024-05945-6","article-title":"A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment","volume":"150","author":"Bielack","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.retram.2025.103551_bib0015","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1177\/10781552221079568","article-title":"Incidence and management of patients with methotrexate delayed elimination in the clinical practice: a Delphi study","volume":"29","author":"Gros","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.retram.2025.103551_bib0016","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.retram.2025.103551_bib0017","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/jcpt.12298","article-title":"High methotrexate exposure and toxicity in children with t(9;22) positive acute lymphoblastic leukaemia treated with imatinib","volume":"40","author":"Loue","year":"2015","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.retram.2025.103551_bib0018","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1097\/MPH.0000000000001816","article-title":"Concurrent imatinib dosing with high-dose methotrexate leads to acute kidney injury and delayed methotrexate clearance in pediatric patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia","volume":"43","author":"Pommert","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"10.1016\/j.retram.2025.103551_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27618","article-title":"Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib","volume":"66","author":"Ramsey","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.retram.2025.103551_bib0020","article-title":"Higher incidence of delayed methotrexate clearance in pediatric acute lymphoblastic leukemia patients treated with imatinib","volume":"2","author":"van der Sluis","year":"2023","journal-title":"EJC Pediatr Oncol"},{"issue":"7","key":"10.1016\/j.retram.2025.103551_bib0021","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(23)00088-1","article-title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial","volume":"10","author":"Hunger","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.retram.2025.103551_bib0022","unstructured":"ClinicalTrials.gov. Imatinib mesylate and combination chemotherapy in treating patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia. 2025. https:\/\/clinicaltrials.gov\/study\/NCT03007147 [accessed 2 June 2025]."},{"issue":"6","key":"10.1016\/j.retram.2025.103551_bib0023","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00280-024-04713-0","article-title":"Hypoalbuminemia in children with acute lymphoblastic leukemia: relation to asparaginase therapy and impact on high dose methotrexate elimination","volume":"94","author":"Christensen","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.retram.2025.103551_bib0024","doi-asserted-by":"crossref","first-page":"300","DOI":"10.21037\/tp-23-615","article-title":"Factors influencing delayed high-dose methotrexate excretion and its correlation with adverse reactions after treatment in children with malignant hematological tumors","volume":"13","author":"Yu","year":"2024","journal-title":"Transl Pediatr"},{"issue":"4","key":"10.1016\/j.retram.2025.103551_bib0025","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3324\/haematol.2019.224774","article-title":"Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen","volume":"105","author":"Kroll","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.retram.2025.103551_bib0026","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3324\/haematol.2009.019778","article-title":"Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia","volume":"95","author":"Buitenkamp","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.retram.2025.103551_bib0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s43046-022-00122-7","article-title":"Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?","volume":"34","author":"Barakat","year":"2022","journal-title":"J Egypt Natl Canc Inst"},{"issue":"6","key":"10.1016\/j.retram.2025.103551_bib0028","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/jcph.1799","article-title":"Effect of body fat on population pharmacokinetics of high-dose methotrexate in pediatric patients with acute lymphoblastic leukemia","volume":"61","author":"Orgel","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.retram.2025.103551_bib0029","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/phar.2390","article-title":"Successful treatment of delayed methotrexate clearance using glucarpidase dosed on ideal body weight in obese patients","volume":"40","author":"Kr\u00fcger","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.retram.2025.103551_bib0030","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ckj\/sfad097","article-title":"Chronic kidney disease in children: an update","volume":"16","author":"Cirillo","year":"2023","journal-title":"Clin Kidn J"},{"issue":"3","key":"10.1016\/j.retram.2025.103551_bib0031","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(19)30800-9","article-title":"Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study","volume":"21","author":"Suh","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.retram.2025.103551_bib0032","first-page":"47","article-title":"Cystatin C-a paradigm of evidence based laboratory medicine","volume":"29","author":"Chew","year":"2008","journal-title":"Clin Biochem Rev"},{"issue":"8","key":"10.1016\/j.retram.2025.103551_bib0033","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/biom14080938","article-title":"Cystatin C as a marker of kidney function in children","volume":"14","author":"Skidmore","year":"2024","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.retram.2025.103551_bib0034","article-title":"Overview of methotrexate toxicity: a comprehensive literature review","volume":"14","author":"Hamed","year":"2022","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.retram.2025.103551_bib0035","first-page":"280","article-title":"2020 ASCO, 2023 NCCN, 2023 MASCC\/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients","volume":"32","author":"Kennedy","year":"2024","journal-title":"Support Care Cancer"},{"issue":"11","key":"10.1016\/j.retram.2025.103551_bib0036","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/sj.leu.2404404","article-title":"High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia","volume":"20","author":"Sk\u00e4rby","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.retram.2025.103551_bib0037","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00280-025-04749-w","article-title":"New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acid","volume":"95","author":"Heldrup","year":"2025","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.retram.2025.103551_bib0038","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30831","article-title":"Methotrexate level discrepancy post-glucarpidase: a pediatric case series and review of literature","volume":"71","author":"Kibby","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.retram.2025.103551_bib0039","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jpha.2019.06.001","article-title":"Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples","volume":"9","author":"Karami","year":"2019","journal-title":"J Pharm Anal"},{"issue":"11","key":"10.1016\/j.retram.2025.103551_bib0040","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1111\/cts.13600","article-title":"Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.Org","volume":"16","author":"Taylor","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"3","key":"10.1016\/j.retram.2025.103551_bib0041","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/cpt.1957","article-title":"MTXPK.Org: a clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase","volume":"108","author":"Taylor","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.retram.2025.103551_bib0042","unstructured":"European Medicines Agency. Voraxaze (glucarpidase): european public assessment report. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/voraxaze [accessed 3 June 2025]."},{"key":"10.1016\/j.retram.2025.103551_bib0043","unstructured":"European Medicines Agency. Voraxaze (glucarpidase): summary of product characteristics [in Italian]. 2022. https:\/\/www.ema.europa.eu\/it\/documents\/product-information\/voraxaze-epar-product-information_it.pdf [accessed 8 November 2024]."},{"issue":"17","key":"10.1016\/j.retram.2025.103551_bib0044","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/blood.2024026211","article-title":"Glucarpidase for treatment of high-dose methotrexate toxicity","volume":"145","author":"Gupta","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.retram.2025.103551_bib0045","series-title":"A practical guide for pediatric nuclear medicine","first-page":"1","article-title":"General Principles in Pediatric Nuclear Medicine","author":"Nadel","year":"2023"},{"issue":"17","key":"10.1016\/j.retram.2025.103551_bib0046","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1002\/cncr.27378","article-title":"Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients","volume":"118","author":"Christensen","year":"2012","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.retram.2025.103551_bib0047","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26395","article-title":"Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia","volume":"64","author":"Svahn","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.retram.2025.103551_bib0048","article-title":"Eight-year national multicenter experience on the use of glucarpidase as effective rescue therapy for delayed methotrexate elimination after high-dose methotrexate cycles administered in children with hemato-oncological diseases","volume":"5","author":"Peccatori","year":"2025","journal-title":"EJC Pediatr Oncol"},{"issue":"4","key":"10.1016\/j.retram.2025.103551_bib0049","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/jha2.799","article-title":"Use of glucarpidase (carboxypeptidase-G2) in pediatric cancer patients: 11-year experience of a tertiary center","volume":"4","author":"Vila","year":"2023","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.retram.2025.103551_bib0050","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","article-title":"Acute kidney injury","volume":"7","author":"Kellum","year":"2021","journal-title":"Nat Rev Dis Primers"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:18:41Z","timestamp":1773832721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318625000601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2452318625000601"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2025.103551","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Italian expert consensus recommendations for the safe administration of high-dose methotrexate in children with cancer and for the use of glucarpidase to manage delayed methotrexate elimination and\/or high-dose methotrexate-induced acute kidney injury","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2025.103551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103551"}}